Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 12/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | WDR5 | P61964 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL784904 | 0.93 | F10 (0.40) | F10WDR5NPY5RCTSS | |
| SCHEMBL784081 | 0.91 | ALDH1A1 (0.43) | F10MEN1KMT2ACTSS | |
| SCHEMBL784261 | 0.91 | ALDH1A1 (0.43) | F10MEN1KMT2ACTSS | |
| SCHEMBL777867 | 0.91 | ALDH1A1 (0.43) | F10MEN1KMT2ACTSS | |
| SCHEMBL785238 | 0.91 | JAK2 (0.41) | JAK2JAK1TYK2 | |
| SCHEMBL784715 | 0.90 | F10 (0.40) | F10CNR1WDR5MEN1KMT2A | |
| SCHEMBL784935 | 0.90 | F10 (0.43) | F10CNR1WDR5CTSS | |
| SCHEMBL784390 | 0.88 | CTSS (0.42) | F10WDR5CTSS | |
| SCHEMBL785754 | 0.88 | ALDH1A1 (0.43) | WDR5MEN1KMT2ACTSS | |
| SCHEMBL785705 | 0.88 | TAS1R3 (0.41) | F10WDR5MEN1KMT2ACTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | claimed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | claimed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | F10 524/4885CNR1 16/4885WDR5 2611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.